18Fluorodeoxyglucose PET Is Prognostic of Progression-Free and Overall Survival in Locally Advanced Pancreas Cancer Treated With Stereotactic Radiotherapy

Slides:

Advertisements

Similar presentations

Incidence of Late Rectal and Urinary Toxicities After Three-Dimensional Conformal Radiotherapy and Intensity-Modulated Radiotherapy for Localized Prostate.

Advertisements

Curative Treatment of Stage I Non-Small-Cell Lung Cancer in Patients With Severe COPD: Stereotactic Radiotherapy Outcomes and Systematic Review David.

Glucose Metabolism Gene Expression Patterns and Tumor Uptake of 18F- Fluorodeoxyglucose After Radiation Treatment George D. Wilson, PhD, Bryan J. Thibodeau,

COSMIC: A Regimen of Intensity Modulated Radiation Therapy Plus Dose-Escalated, Raster-Scanned Carbon Ion Boost for Malignant Salivary Gland Tumors: Results.

Correlation of 18F-FDG Avid Volumes on Pre–Radiation Therapy and Post–Radiation Therapy FDG PET Scans in Recurrent Lung Cancer Nadya Shusharina, PhD,

Pre- and per-treatment 18F-FDG PET/CT parameters to predict recurrence and survival in cervical cancer Julie Leseur, Geoffrey Roman-Jimenez, Anne Devillers,

The Case for Prostate Brachytherapy in the Affordable Care Act Era

Toxicity of Gamma Knife Radiosurgery in the Treatment of Intracranial Tumors in Patients With Collagen Vascular Diseases or Multiple Sclerosis Dot Lowell,

The Role of Diffusion-Weighted Magnetic Resonance Imaging in the Treatment Response Evaluation of Hepatocellular Carcinoma Patients Treated With Radiation.

A Double-Blind Placebo-Controlled Randomized Clinical Trial With Magnesium Oxide to Reduce Intrafraction Prostate Motion for Prostate Cancer Radiotherapy

Pre-operative hyperfractionated radiotherapy and concurrent 5-fu/cisplatin for locally advanced esophageal cancer - the impact of 18-F-fluoro-deoxy-d-glucose.

The Use of Hormone Therapy Alone Versus Hormone Therapy and Radiation Therapy for Breast Cancer in Elderly Women: A Population-Based Study Alan M. Nichol,

Cost-Effectiveness Analysis of Stereotactic Body Radiotherapy and Radiofrequency Ablation for Medically Inoperable, Early-Stage Non–Small Cell Lung Cancer

Boron Neutron Capture Therapy in the Treatment of Locally Recurred Head-and-Neck Cancer: Final Analysis of a Phase I/II Trial Leena Kankaanranta, M.D.,

A Dose Escalation and Pharmacodynamic Study of Triapine and Radiation in Patients With Locally Advanced Pancreas Cancer Ludmila Katherine Martin, MD,

Dose-Volume Histogram Predictors of Chronic Gastrointestinal Complications After Radical Hysterectomy and Postoperative Concurrent Nedaplatin-Based Chemoradiation.

Lactate-Base 1H Magnetic Spectroscopy Does Not Predict Response and Outcomes in Patients With Stage IV Head and Neck Squamous Cell Carcinoma Q. Le, A.

Higher Biologically Effective Dose of Radiotherapy Is Associated With Improved Outcomes for Locally Advanced Non–Small Cell Lung Carcinoma Treated With.

Individualized Positron Emission Tomography–Based Isotoxic Accelerated Radiation Therapy Is Cost-Effective Compared With Conventional Radiation Therapy:

Stereotactic Body Radiation Therapy for Locally Advanced and Borderline Resectable Pancreatic Cancer Is Effective and Well Tolerated Michael D. Chuong,

Close or Positive Margins After Mastectomy for DCIS: Pattern of Relapse and Potential Indications for Radiotherapy Afshin Rashtian, M.D., Shawn Iganej,

Ductal Carcinoma In Situ With Microinvasion: Prognostic Implications, Long-Term Outcomes, and Role of Axillary Evaluation Rahul R. Parikh, M.D., Bruce.

The impact of ipsilateral breast tumor recurrence on cause specific survival in DCIS patients treated with breast conserving therapy or mastectomy C.

Morten Hoyer, Ph. D. , Henrik Roed, D. M. Sc

Jerry D Slater, M. D. , Carl J Rossi, M. D. , Les T Yonemoto, M. D

Five-Year Biochemical Results, Toxicity, and Patient-Reported Quality of Life After Delivery of Dose-Escalated Image Guided Proton Therapy for Prostate.

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Marie Florescu,

A New Model for Imaging and Radiation Therapy Quality Assurance in the National Clinical Trials Network of the National Cancer Institute Thomas J. FitzGerald,

Obituary and Tribute to John “Jack” Francis Fowler, PhD, DSc ( )

Continuing Risk of Ipsilateral Breast Relapse After Breast-Conserving Therapy at Long- Term Follow-up Bas Kreike, M.D., Augustinus A.M. Hart, M.Sc., Tony.

Timing of Radiation Therapy and Chemotherapy After Breast-Conserving Surgery for Node-Positive Breast Cancer: Long-Term Results From International Breast.

Dose–Volume Relationships Associated With Temporal Lobe Radiation Necrosis After Skull Base Proton Beam Therapy Mark W. McDonald, MD, Okechukwu R. Linton,

Lifetime Increased Cancer Risk in Mice Following Exposure to Clinical Proton Beam– Generated Neutrons Leo E. Gerweck, PhD, Peigen Huang, MD, Hsiao-Ming.

Higher-Than-Conventional Radiation Doses in Localized Prostate Cancer Treatment: A Meta-analysis of Randomized, Controlled Trials Gustavo Arruda Viani,

Salvage Stereotactic Body Radiotherapy (SBRT) Following In-Field Failure of Initial SBRT for Spinal Metastases Isabelle Thibault, MD, Mikki Campbell,

Adjuvant Therapy in High-Risk Stage III Cutaneous Melanoma

International Journal of Radiation Oncology • Biology • Physics

High-Dose-Rate Brachytherapy Boost for Prostate Cancer: Comparison of Two Different Fractionation Schemes Tania Kaprealian, M.D., Vivian Weinberg, Ph.D.,

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prospective Assessment of Patient-Rated Symptoms Following Whole Brain Radiotherapy for Brain Metastases Edward Chow, MBBS, Lori Davis, PhD, Lori Holden,

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901 Stephen L. Graziano,

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Marie Florescu,

Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes Julie E. Bauman, MD, Michael.

Patient-reported symptoms and performance status before palliative radiotherapy in geriatric cancer patients (octogenarians) Carsten Nieder, Thomas A.

Gemcitabine and Irinotecan for Patients with Untreated Extensive Stage Small Cell Lung Cancer: SWOG 0119 Wallace Akerley, MD, Jason McCoy, MS, Paul J.

Electronic Updates for JTO Readers

Role of CT and PET Imaging in Predicting Tumor Recurrence and Survival in Patients with Lung Adenocarcinoma Ho Yun Lee, MD, PhD, So Won Lee, MD, Kyung.

Pretreatment Anemia Portends Poor Survival and Nonlocal Disease Progression in Patients with Stage I Non–Small Cell Lung Cancer Treated with Stereotactic.

Maximum Standardized Uptake Value on FDG-PET Is a Strong Predictor of Overall and Disease-Free Survival for Non–Small-Cell Lung Cancer Patients after.

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430 Thomas E.

Photodynamic Therapy for Early Stage Central Type of Lung Cancer

Preliminary Report of Late Recurrences, at 5 Years or More, after Stereotactic Body Radiation Therapy for Non-small Cell Lung Cancer Yukinori Matsuo,

George Blumenschein, MD, John V. Heymach, MD, PhD

Relevance of Platinum-Sensitivity Status in Relapsed/Refractory Extensive-Stage Small- Cell Lung Cancer in the Modern Era: A Patient-Level Analysis of.

High SUVmax on FDG-PET Indicates Pleomorphic Subtype in Epithelioid Malignant Pleural Mesothelioma: Supportive Evidence to Reclassify Pleomorphic as Nonepithelioid.

Role of CT and PET Imaging in Predicting Tumor Recurrence and Survival in Patients with Lung Adenocarcinoma Ho Yun Lee, MD, PhD, So Won Lee, MD, Kyung.

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Absence of a Relationship between Tumor 18F-fluorodeoxyglucose Standardized Uptake Value and Survival in Patients Treated with Definitive Radiotherapy.

Treatment of Colorectal Cancer

Gemcitabine in Brief versus Prolonged Low-Dose Infusion, both Combined with Cisplatin, for Advanced Non-small Cell Lung Cancer: A Randomized Phase II.

Gaurav Marwaha, MD, Kevin L. Stephans, MD, Neil M

Primary Tumor Standardized Uptake Value Measured on F18-Fluorodeoxyglucose Positron Emission Tomography Is of Prediction Value for Survival and Local.

International Thymic Malignancies Interest Group: A Way Forward

Impact of Tumor Size on Local Control and Pneumonitis After Stereotactic Body Radiation Therapy for Lung Tumors Sean M. Parker, BS, R. Alfredo Siochi,

Stage I Non-small Cell Lung Cancer: Results for Surgery in a Patterns-of-Care Study in Sydney and for High-Dose Concurrent End-Phase Boost Accelerated.

Role of Positron Emission Tomography/Computed Tomography Findings for Adjuvant Chemotherapy Indications in Stage T1b-2aN0M0 Lung Adenocarcinoma Shinsuke.

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

Dose-Escalated Stereotactic Body Radiotherapy (SBRT) as a Salvage Treatment for Two Cases with Relapsed Peripheral Lung Cancer After Initial SBRT Shuichi.

Presentation transcript:

18Fluorodeoxyglucose PET Is Prognostic of Progression-Free and Overall Survival in Locally Advanced Pancreas Cancer Treated With Stereotactic Radiotherapy Devin Schellenberg, M.D., Andy Quon, M.D., A. Yuriko Minn, M.D., Edward E. Graves, Ph.D., Pamela Kunz, M.D., James M. Ford, M.D., Ph.D., George A. Fisher, M.D., Karyn A. Goodman, M.D., Albert C. Koong, M.D., Ph.D., Daniel T. Chang, M.D. International Journal of Radiation Oncology • Biology • Physics Volume 77, Issue 5, Pages 1420-1425 (August 2010) DOI: 10.1016/j.ijrobp.2009.06.049 Copyright © 2010 Elsevier Inc. Terms and Conditions

Fig. 1 Overall survival from diagnosis for all patients. International Journal of Radiation Oncology • Biology • Physics 2010 77, 1420-1425DOI: (10.1016/j.ijrobp.2009.06.049) Copyright © 2010 Elsevier Inc. Terms and Conditions

Fig. 2 Overall survival of patients stratified by maximum standardized uptake value (SUVmax) above and below the median (p <0.01). International Journal of Radiation Oncology • Biology • Physics 2010 77, 1420-1425DOI: (10.1016/j.ijrobp.2009.06.049) Copyright © 2010 Elsevier Inc. Terms and Conditions

Fig. 3 Overall survival of patients stratified by metabolic tumor burden (MTB) above or below the median (p = 0.01). International Journal of Radiation Oncology • Biology • Physics 2010 77, 1420-1425DOI: (10.1016/j.ijrobp.2009.06.049) Copyright © 2010 Elsevier Inc. Terms and Conditions

Fig. 4 Overall survival of patients stratified by risk group using both metabolic tumor burden (MTB) and standardized uptake value (SUVmax); p = 0.02. International Journal of Radiation Oncology • Biology • Physics 2010 77, 1420-1425DOI: (10.1016/j.ijrobp.2009.06.049) Copyright © 2010 Elsevier Inc. Terms and Conditions

Fig. 5 Overall survival of patients stratified by clinical maximum standardized uptake value (SUVmax) cutoffs of <5, 5–10, or >10 (p <0.01). International Journal of Radiation Oncology • Biology • Physics 2010 77, 1420-1425DOI: (10.1016/j.ijrobp.2009.06.049) Copyright © 2010 Elsevier Inc. Terms and Conditions